CLAIMS

What is claimed is:

- A method for treating sickle-cell disease in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified annexin protein, wherein said modified annexin protein comprises an annexin protein coupled to at least one additional protein.
 - 2. The method of claim 1, wherein said modified annexin protein is an annexin dimer.
 - 3. The method of claim 1, wherein said additional protein is the Fc portion of immunoglobulin.
 - 4. The method of claim 1, wherein said additional protein has a molecular weight of at least 30 kDa.
 - 5. The method of claim 1, wherein said additional protein is an additional annexin protein.
 - 6. The method of claim 1, wherein said annexin protein is an annexin V protein.
 - 7. The method of claim 6, wherein said annexin V protein comprises an amino acid sequence selected from the group consisting of:
 - a) SEQ ID NO:3; and
 - b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:3.
 - 8. The method of claim 6, wherein said additional protein is an additional annexin V protein.

- 9. The method of claim 8, wherein said additional annexin V protein comprises an amino acid sequence selected from the group consisting of:
 - a) SEQ ID NO:3; and
 - b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:3.
- 10. The method of claim 8, wherein said isolated modified annexin protein comprises an amino acid sequence selected from the group consisting of:
 - a) SEQ ID NO:6; and
 - b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:6.
- 11. A method for treating sickle-cell disease in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified annexin protein, wherein said modified annexin protein comprises an annexin protein coupled to polyethylene glycol.
 - 12. The method of claim 11, wherein said polyethylene glycol has a molecular weight of at least 10 kDa.
 - 13. The method of claim 11, wherein each modified annexin protein comprises at least two polyethylene glycol chains.
 - 14. The method of claim 1, wherein said annexin protein is an annexin V protein
 - 15. The method of claim 14, wherein said annexin V protein comprises an amino acid sequence selected from the group consisting of:

- a) an amino acid sequence selected from the group consisting of SEQ
 ID NO:3 and SEQ ID NO:6; and
- b) an amino acid sequence selected from the group consisting of an amino acid sequence having at least 95% sequence identity to an amino acid sequence of a).